BRCA1 and ovarian cancer: Although alkylating agents display similar selectivity to cisplatin in targeting BRCA1/2‐deficiencies, they have largely been abandoned for clinical use in breast and ovarian cancers, due to early sub‐optimal results in non‐stratified patient populations (Williams et al, 1985).